GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
Betsy Goodfellow | October 30, 2023 | News story | Medical Communications | Cancer, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed Jemperli (dostarlimab) plus standard of care chemotherapy (carboplatin and paclitaxel), followed by dostarimab as a single agent, compared to placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.
The trial met its primary endpoint of overall survival (OS) and demonstrated a statistically significant and clinically meaningful benefit in the patient population. Previously, the trial also met its other primary endpoint of progression-free survival (PFS).
The safety of the drugs used in the trial remained consistent with their known safety profiles, with the most common treatment-emergent adverse events being nausea, alopecia, fatigue, peripheral neuropathy, anaemia, arthralgia, constipation, diarrhoea and myalgia.
Full results are expected to be published in a medical journal and presented at an upcoming scientific meeting.
Hesham Abdullah, senior vice president and global head of Oncology R&D at GSK, commented: “With today’s headline results from part 1 of the phase 3 RUBY trial, dostarlimab plus chemotherapy has become the only immuno-therapy combination to show a survival benefit in this broader patient population in this treatment setting. We look forward to sharing detailed results of this analysis with regulatory authorities and the larger scientific community.”
Betsy Goodfellow
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
